Trial Profile
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus H7N9 vaccines (Primary) ; AS03A
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 30 Jul 2020 Status changed from active, no longer recruiting to completed.
- 16 Jul 2020 Planned End Date changed from 30 Jun 2020 to 31 Jul 2020.
- 16 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Jul 2020.